H.C. Wainwright Reiterates Neutral Rating on Aldeyra Therapeutics (ALDX)

September 30, 2026 7:20 AM

H.C. Wainwright analyst Matt Caufield reiterated a Neutral rating and $2.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found